Aldoxorubicin (LADR-7)
Soft Tissue Sarcoma
About LadRx
LadRx is a clinical-stage oncology company focused on improving cancer chemotherapy through its proprietary linker-activated drug release (LADR) platform. Its mission is to develop safer, more effective treatments by targeting the release of potent chemotherapeutics within the acidic tumor microenvironment. The company's strategy hinges on advancing its lead asset, aldoxorubicin, for soft tissue sarcoma and exploring its potential in other malignancies, while navigating the significant capital and execution risks inherent in late-stage drug development. As a micro-cap public entity, LadRx operates with a lean structure, deriving its value from its clinical IP and platform technology.
View full company profileAbout LadRx
LadRx is a clinical-stage oncology company focused on improving cancer chemotherapy through its proprietary linker-activated drug release (LADR) platform. Its mission is to develop safer, more effective treatments by targeting the release of potent chemotherapeutics within the acidic tumor microenvironment. The company's strategy hinges on advancing its lead asset, aldoxorubicin, for soft tissue sarcoma and exploring its potential in other malignancies, while navigating the significant capital and execution risks inherent in late-stage drug development. As a micro-cap public entity, LadRx operates with a lean structure, deriving its value from its clinical IP and platform technology.
View full company profileAbout LadRx
LadRx is a clinical-stage oncology company focused on improving cancer chemotherapy through its proprietary linker-activated drug release (LADR) platform. Its mission is to develop safer, more effective treatments by targeting the release of potent chemotherapeutics within the acidic tumor microenvironment. The company's strategy hinges on advancing its lead asset, aldoxorubicin, for soft tissue sarcoma and exploring its potential in other malignancies, while navigating the significant capital and execution risks inherent in late-stage drug development. As a micro-cap public entity, LadRx operates with a lean structure, deriving its value from its clinical IP and platform technology.
View full company profileTherapeutic Areas
Other Soft Tissue Sarcoma Drugs
| Drug | Company | Phase |
|---|---|---|
| Yondelis (trabectedin) | PharmaMar | Approved |
| ADI-PEG 20 (pegargiminase) | Polaris Pharma | Phase 3 |
| ADCE-D01 | Adcendo | Phase 1/2 |
| Tissue Orientation System Clinical Expansion | Vector Surgical | Commercial |
| NBTXR3 | Nanobiotix | Phase II/III |